Thomas Olencki
Overview
Explore the profile of Thomas Olencki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
3100
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Damante M, Huntoon K, Gibbs D, Pezzutti D, Olencki T, Elder J
Neurosurg Focus
. 2023 Aug;
55(2):E2.
PMID: 37527670
Objective: Immune checkpoint inhibitor (ICI) efficacy in the treatment of metastatic renal cell carcinoma (RCC) without brain metastases (BMs) is well established in several clinical trials; however, patients with BMs...
2.
Huntoon K, Damante M, Wang J, Olencki T, Elder J
Curr Probl Cancer
. 2021 Nov;
46(2):100805.
PMID: 34836657
Patient survival with renal cell carcinoma (RCC) has improved with the use of molecular targeted agents and immunotherapy. Given the potential activity of these agents in treating brain metastases, the...
3.
Nghiem P, Bhatia S, Lipson E, Sharfman W, Kudchadkar R, Brohl A, et al.
J Immunother Cancer
. 2021 Apr;
9(4).
PMID: 33879601
Background: Merkel cell carcinoma (MCC) is an aggressive skin cancer associated with poor survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of durable tumor regression compared with...
4.
Ornstein M, Pal S, Wood L, Tomer J, Hobbs B, Jia X, et al.
Lancet Oncol
. 2019 Aug;
20(10):1386-1394.
PMID: 31427205
Background: Checkpoint inhibitor therapy is a standard of care for patients with metastatic renal cell carcinoma. Treatment options after checkpoint inhibitor therapy include vascular endothelial growth factor receptor (VEGF-R) tyrosine...
5.
Singh P, Pandey D, Rovin B, Pesavento T, Olencki T
Cureus
. 2019 Jul;
11(5):e4658.
PMID: 31328051
Approximately 7% of deceased donors have unknown cancer at the time of organ procurement. More than half of these have no apparent contraindication to organ donation. The commonest transmitted malignancy...
6.
McMichael E, Benner B, Atwal L, Courtney N, Mo X, Davis M, et al.
Clin Cancer Res
. 2019 May;
25(16):4955-4965.
PMID: 31142501
Purpose: mAbs including cetuximab can induce antibody-dependent cellular cytotoxicity (ADCC) and cytokine production mediated via innate immune cells with the ability to recognize mAb-coated tumors. Preclinical modeling has shown that...
7.
Nghiem P, Bhatia S, Lipson E, Sharfman W, Kudchadkar R, Brohl A, et al.
J Clin Oncol
. 2019 Feb;
37(9):693-702.
PMID: 30726175
Purpose: Merkel cell carcinoma (MCC) is an aggressive skin cancer often caused by the Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway inhibitors for advanced MCC (aMCC) demonstrate...
8.
Singh P, Visger Von J, Prosek J, Rovin B, Pesavento T, Olencki T, et al.
Transplantation
. 2018 Oct;
103(2):e52-e53.
PMID: 30365468
No abstract available.
9.
Choueiri T, Hessel C, Halabi S, Sanford B, Michaelson M, Hahn O, et al.
Eur J Cancer
. 2018 Oct;
103:287.
PMID: 30270112
No abstract available.
10.
Bichakjian C, Olencki T, Aasi S, Alam M, Andersen J, Blitzblau R, et al.
J Natl Compr Canc Netw
. 2018 Jun;
16(6):742-774.
PMID: 29891526
This selection from the NCCN Guidelines for Merkel Cell Carcinoma (MCC) focuses on areas impacted by recently emerging data, including sections describing MCC risk factors, diagnosis, workup, follow-up, and management...